COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Myriad Genetic Laboratories, Inc.. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 10, 2026 to Mar 10, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PJG appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P190014, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 320 Wankara Way, Salt Lake City, UT, 84108. Recorded on P190014/S011, decision dated Mar 10, 2026.
Device categories in this collection
Cancer-related germline gene mutation detection system.
Changes described in PMA records
FDA’s recorded scope: Approval to update the MyChoice CDx assay labeling from a complementary diagnostic to a companion diagnostic to aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline or somatic BRCA1 and BRCA2 mutations and/or a positive genomic instability score, who are eligible or may become eligible for treatment with Zejula (niraparib).
Mar 10, 2026 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.